Literature DB >> 30546575

Diphenhydramine and QT prolongation - A rare cardiac side effect of a drug used in common practice.

Aditya Shah1, Tariq Yousuf1, Jeffrey Ziffra1, Ali Zaidi1, Rashmi Raghuvir1.   

Abstract

There have been few cases in recent times where QT interval prolongation has been studied with regards to the use of diphenhydramine. We present a case of a patient who presented because of shortness of breath and needed emergent hemodialysis; during the course of which he developed prolonged QT interval on electrocardiography, which was correlated interestingly with the use of diphenhydramine. Pruritus is a common symptom experienced by dialysis patients. A less known, but rare side effect of diphenhydramine is prolongation of QT interval. The histamine H1 receptor antagonist diphenhydramine inhibits the fast sodium channels and at higher concentrations inhibits the repolarizing potassium channels which leads to prolongation of the action potential and the QT interval. Diphenhydramine toxicity is dose-dependent with a critical dose limit of 1.0 g. Although a lot is known about the potential side effects of antihistamines, only a few cases have cited the cardiac side effects. Thus, it is important for the clinician to be aware of this potentially serious consequence of a commonly used drug, especially in the end-stage renal disease population. It is important for clinicians to be aware of this rare yet dangerous side effect of diphenhydramine. <Learning objective: Although a lot is known about the potential side effects of antihistamine drugs little is described regarding cardiac side effects. Some antihistamines such as terfenadine have been discontinued from the US market due to prolonged QT interval; therefore, it is important for the clinician to be aware of potentially serious consequences of a commonly used drug such as diphenhydramine. We describe a case of a patient who developed QT prolongation with a temporal association with diphenhydramine usage.>.

Entities:  

Keywords:  Arrhythmias; Cardiac; Dialysis; Diphenhydramine

Year:  2015        PMID: 30546575      PMCID: PMC6281831          DOI: 10.1016/j.jccase.2015.06.002

Source DB:  PubMed          Journal:  J Cardiol Cases        ISSN: 1878-5409


  6 in total

1.  Diphenhydramine induced QT prolongation and torsade de pointes: An uncommon effect of a common drug.

Authors:  Zehra Husain; Khursheed Hussain; Rajiv Nair; Russell Steinman
Journal:  Cardiol J       Date:  2010       Impact factor: 2.737

2.  QT interval prolongation in diphenhydramine toxicity.

Authors:  Abhash C Thakur; Ahmad K Aslam; Ahmed F Aslam; Balendu C Vasavada; Terrence J Sacchi; Ijaz A Khan
Journal:  Int J Cardiol       Date:  2005-02-15       Impact factor: 4.164

3.  Electrocardiographic findings in patients with diphenhydramine overdose.

Authors:  W Zareba; A J Moss; S Z Rosero; R Hajj-Ali; J Konecki; M Andrews
Journal:  Am J Cardiol       Date:  1997-11-01       Impact factor: 2.778

4.  Prolonged QT interval with markedly abnormal ventricular repolarization in diphenhydramine overdose.

Authors:  John W Sype; Ijaz A Khan
Journal:  Int J Cardiol       Date:  2005-03-18       Impact factor: 4.164

5.  Effects of the antitussive drug cloperastine on ventricular repolarization in halothane-anesthetized guinea pigs.

Authors:  Akira Takahara; Kaori Fujiwara; Atsushi Ohtsuki; Takayuki Oka; Iyuki Namekata; Hikaru Tanaka
Journal:  J Pharmacol Sci       Date:  2012-10-06       Impact factor: 3.337

6.  Diphenhydramine dependence through deep intramuscular injection resulting in myonecrosis and prolonged QT interval.

Authors:  T-Y Chen; Y-W Yeh; S-C Kuo; C-Y Chen; T-P Lin; C-C Chang
Journal:  J Clin Pharm Ther       Date:  2014-03-05       Impact factor: 2.512

  6 in total
  4 in total

Review 1.  Measurement and Management of QT Interval Prolongation for General Physicians.

Authors:  Praveen Indraratna; Daniel Tardo; Madeline Delves; Richard Szirt; Ben Ng
Journal:  J Gen Intern Med       Date:  2019-10-25       Impact factor: 5.128

2.  Evaluation of the potential for QTc prolongation with avelumab.

Authors:  Yulia Vugmeyster; Gülseren Güzel; Meliessa Hennessy; Anja H Loos; Haiqing Dai
Journal:  Cancer Chemother Pharmacol       Date:  2019-09-03       Impact factor: 3.333

Review 3.  Toward a broader view of mechanisms of drug cardiotoxicity.

Authors:  Polina Mamoshina; Blanca Rodriguez; Alfonso Bueno-Orovio
Journal:  Cell Rep Med       Date:  2021-03-16

4.  The Role of Dexmedetomidine in Pediatric Patients Presenting with an Anticholinergic Toxidrome.

Authors:  Mitchell Zekhtser; Erin Carroll; Molly Boyd; Shashikanth Ambati
Journal:  Case Rep Crit Care       Date:  2021-08-28
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.